News
抄読会要旨 御任玲美
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
6/10sat.16:00~医局説明会を開催します☆
熊本大学 呼吸器内科